Q-omics provides the consensus-scored LIN54 profile across patient tissues and cancer cell-line models. LIN54 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LIN54 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, LIN54 RNA expression shows 20,549 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where LIN54 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LIN54 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LIN54 survival associations across molecular data types. LIN54 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LIN54 RNA expression–survival associations across cancer types. High LIN54 expression shows unfavorable associations in MESO, UVM, LUAD and LIHC, but favorable associations in KIRC and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LIN54 RNA expression.
This table summarizes LIN54 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for LIN54. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LIN54 shows lower tumor expression in THCA and higher tumor expression in KIRC, LUAD, BRCA, BLCA and LIHC. The KIRC box plot shows higher LIN54 RNA expression in tumor versus normal tissue (log2 FC = +0.278, t-test p < 0.001).
This table shows molecular features associated with LIN54 in patient tissues and cancer cell lines. In patient samples, LIN54 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, LIN54 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
